In particular, the presence of the PACSIN2 TT genotype in ALL patients was associated with reduced TPMT activity during the maintenance phase of treatment and also with the incidence of severe gastrointestinal toxicities during the consolidation therapy. The gene discussed is TPMT; the disease is acute lymphoblastic leukemia.